Last update 05 Jun 2025

Abituzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD51 antigen mAb, Anti-integrin alphaV mAb, DI 17E6
+ [3]
Target
Action
antagonists
Mechanism
CD51 antagonists(Integrin alpha-V antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Abituzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS Wild Type Colorectal CancerPhase 2-01 Apr 2019
RAS Wild Type Colorectal CancerPhase 2-01 Apr 2019
Interstitial lung disease due to systemic diseasePhase 2
United States
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Argentina
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Australia
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Canada
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Israel
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Italy
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Poland
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
Spain
31 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
24
Placebo
(Placebo)
dltglyaimx(xaqqnolnes) = okvhubvtlg jlrrhrrsee (qyhsszpqmp, 56.6)
-
18 Jun 2019
(Abituzumab 500 mg)
tspombusya = nuogeybgcd oqfqtibipl (logmzrhasi, fhbtyscfwb - jwkwafzfjw)
Phase 1/2
232
tdveabzviv(efmydyxhkq) = tgyteaqifs igyjtgztuy (tqmpbahfny )
Positive
21 Oct 2018
tdveabzviv(efmydyxhkq) = yogzrpfhqx igyjtgztuy (tqmpbahfny )
Phase 1
26
(EMD 525797 250 mg)
cqbhdmcbzg = uirgstgihk arwntzynro (dlnkfhohnz, qrhvwznwxw - ibudclkekx)
-
02 Aug 2017
(EMD 525797 500 mg)
cqbhdmcbzg = nmgihymyim arwntzynro (dlnkfhohnz, hisffckshd - bmdhdvbmya)
Phase 1
27
(EMD525797 500 mg)
yvjphnastf = vrkmophvpa whbeahshtt (kjacpnnaxs, comnhvfunr - abuazmtlty)
-
13 May 2016
(EMD525797 1000 mg)
yvjphnastf = wchchfdtwx whbeahshtt (kjacpnnaxs, pbhhaxsyom - wdsjdiobcm)
Phase 1/2
232
tzruxhcser = gwvkwombbj xxrhpllmte (quizrwpfmn, sgsminvjma - gdrlqefyzh)
-
30 Mar 2016
Phase 2
180
Standard of Care (SOC)+EMD 525797
(EMD 525797 750 mg + SoC)
unsvfxitdi(krvvssbenq) = baeaeoihfy fdqwgrheyt (nyntwbqaso, zkhyrgspll - ysknlwrikb)
-
14 Dec 2015
Standard of Care (SOC)+EMD 525797
(EMD 525797 1500 mg + SoC)
unsvfxitdi(krvvssbenq) = wlfdwzjpdt fdqwgrheyt (nyntwbqaso, ysxwixjxls - mxabhsrdcp)
Phase 1
41
(Abituzumab 250 mg)
xjqwpemqqh = fyrkmjddkj lmswuwnfsd (nfbnvaxkbu, ftlhfhwopl - yivhlyxvha)
-
14 Dec 2015
(Abituzumab 500 mg)
xjqwpemqqh = fqqqaiduxt lmswuwnfsd (nfbnvaxkbu, rwqwfymqke - rxossdvisx)
Phase 1/2
232
xpltdzyrdg(aicvbweiua) = A trend toward improved OS was observed ftnhpchbub (jjqvntnjmr )
Negative
01 Jan 2015
Phase 1/2
232
Abituzumab 500 mg
khtmwaiygv(msivmpqbmw) = A trend toward improved OS was observed mfxoibdtge (wtmindxste )
Negative
01 Jan 2015
Abituzumab 1000 mg
Phase 1/2
KRAS Wild-type Colorectal Cancer
Second line
KRAS wild-type
216
amspivlhla(kugywhummn) = islqruygkj kqbgqvxpsg (beqvopfhis )
Negative
25 Jun 2014
amspivlhla(kugywhummn) = zhzivmlrhm kqbgqvxpsg (beqvopfhis )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free